WO2004021967A2 - Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent - Google Patents
Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent Download PDFInfo
- Publication number
- WO2004021967A2 WO2004021967A2 PCT/EP2003/010692 EP0310692W WO2004021967A2 WO 2004021967 A2 WO2004021967 A2 WO 2004021967A2 EP 0310692 W EP0310692 W EP 0310692W WO 2004021967 A2 WO2004021967 A2 WO 2004021967A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- depigmenting
- skin
- composition
- adapalene
- depigmenting agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- Depigmenting composition for the skirt comprising adapalene and at least one depigmenting agent
- the invention relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, adapalene (6- [3- (1-adamantyl) -4-methoxyphenyl] - 2-naphthanoic acid) and at least one depigmenting agent and its pharmaceutical or cosmetic use.
- the composition according to the invention may also contain a sunscreen.
- A. M. Kligman describes, in patent
- Retinoic acid (tretinoin) is known to have on its own a skin depigmenting activity (Guevara I. A. and Pandya A. G. Int. J. Dermatol . 40, 210-215 (2001) unlike adapalene which has no depigmenting activity as is, shown in Example 6 below.
- adapalene which has no depigmenting activity as is, shown in Example 6 below.
- a depigmenting agent in a depigmenting composition containing a sunscreen or not .
- the applicant has discovered, surprisingly, that the combination of adapalene and a depigmenting agent made it possible to obtain a much more rapid depigmenting response than that obtained with the depigmenting agent alone.
- the invention therefore relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, adapalene and at least one depigmenting agent .
- physiologically acceptable medium is understood to mean a medium compatible with the skin, the mucous membranes and/or the superficial body growths.
- depigmenting agent is understood to mean any active agent having a skin depigmenting activity. This activity makes it possible to reduce the already existing pigmentation of the skin and also to prevent any additional pigmentation above the natural pigmentation.
- depigmenting agent by way of nonlimiting example, phenolic derivatives, such as hydroquinone, hydroquinone monoethyl ether, hydroquinone monobenzyl ether or 4-hydroxyanisole; kojic acid and its derivatives; azelaic acid and its derivatives; linoleic acid; resorcinol and its derivatives; ellagic acid; hydroxy acids such as glycolic acid; ascorbic acid and its derivatives, in particular ascorbyl glucoside; zinc peroxide; and mercury chloride, arbutin and its derivatives such as those described in applications EP-895 779 and EP-524 109; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular N-cholesteryloxy- carbonyl-para-aminophenol and N-ethyloxycarbonyl-para- aminophenol; iminophenol derivatives, in particular those described in application WO 99/22707; L-2-o
- the invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, adapalene, at least one depigmenting agent and at least one sunscreen.
- the composition according to the invention advantageously comprises between 0.0001 and 20% by weight of adapalene relative to the total weight of the composition and between 0.0001 and 20% by weight of depigmenting agent relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of adapalene relative to the total weight of the composition and between 0.025 and 10% by weight of depigmenting agent relative to the total weight of the composition.
- the composition may also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition.
- sunscreens there may be mentioned, by way of nonlimiting example, physical sunscreens such as titanium dioxide, zinc oxide, and chemical sunscreens such as octocrylene, ethylhexyl methoxycinnamate, octyl salicylate, avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane or mixtures thereof .
- Each sunscreen may be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
- compositions according to the invention may additionally comprise any additive customarily used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, colourings, customary inorganic or organic bases or acids, perfumes, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self- tanning compounds, skin soothing and protecting agents such as allantoin.
- any additive customarily used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, colourings, customary inorganic or organic bases or acids, perfumes, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self- tanning compounds, skin soothing and protecting agents such as allantoin.
- additives may be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
- EDTA ethylenediaminetetraacetic acid
- preservatives benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea and parabens.
- humectants glycerin and sorbitol .
- the subject of the present invention is also the composition according to the invention as described above as a medicament .
- the invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
- compositions of the invention are particularly suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post- inflammatory hyperpigmentations due to an abrasion, a burn, a scar, a dermatosis, a contact allergy; naevi, hyperpigmentations with a genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other hyperpigmentary lesions.
- hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post- inflammatory hyperpigmentations due to an abrasion, a burn, a scar, a dermatosis, a contact allergy; naevi, hyperpigmentations with a genetic determinism, hyperpigmentations of metabolic or drug
- compositions according to the invention also find application in the cosmetic field, in particular in protection against the harmful effects of the sun, for preventing and/or combating photoinduced or chronologic ageing of the skin and of the superficial body growths .
- the invention also relates to a method for a nontherapeutic cosmetic treatment for beautifying the skin and/or for improving its surface appearance, characterized in that a composition comprising adapalene and at least one depigmenting agent is applied to the skin and/or its superficial body growths .
- Example 1 In the compositions below (Examples 1 to 5) , the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition.
- Example 1 1 In the compositions below (Examples 1 to 5) , the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition.
- Example 3 This composition should be applied once per day until complete depigmentation is obtained for the treatment of melasma.
- Example 5 This composition should be applied twice per day until complete depigmentation is obtained for the treatment of melasma.
- This composition should be applied once per day until complete depigmentation is obtained for the treatment of chloasma.
- Example 6 Measurement of the depigmenting activity of the combination of adapalene and a depigmenting agent
- the evaluation of the depigmenting and/or anti-pigmenting activity of hydroquinone 3% and Adapalene 0.1% alone or in combination for 8 weeks is carried out on the tail of SKH HR2 mice which is irradiated or not with ultraviolet B.
- the tail of the SKH:HR2 mouse is naturally pigmented and this pigmentation increases under the effect of repeated UVB irradiation.
- the depigmenting activity is measured on, the natural pigmentation after application of the test product to the tail of nonirradiated animals.
- the anti-pigmenting activity is measured by the inhibition of the induction of the UV-induced pigmentation: the test product is applied to the tail of animals irradiated with UVB.
- the treatment is carried out for 5 days per week for 8 weeks. 20 ⁇ l of test product, diluted in acetone, are applied to the tail in a deferred manner: hydroquinone in the morning and adapalene 4 h later. On the days for irradiation, the treatment is applied after irradiation.
- the animals are irradiated 3 times per week for 8 weeks (Monday, Wednesday, Friday) at the dose of 90 mJ/cm 2 of UVB.
- the evaluation is made by different clinical observations: once per week before irradiation, the pigmentation is evaluated by virtue of a score on a scale from 0 to .
- the distribution of the scores is the following:
- Figure 1 represents the kinetics for the scores of pigmentation of the mouse skin as a function of the treatment time with or without irradiation with ultraviolet B (up to 8 weeks of treatment) with ( ⁇ ) UVB + acetone, ( ⁇ ) UVB + Adapalene, ( ) UVB + hydroquinone, (•) UVB+hydroquinone+adapalene, (D] non- irradiated skin + acetone, ( ⁇ ) nonirridiated skin + adapalene (o) nonirradiated skin + hydroquinone (V) nonirradiated skin + hydroquinone + adapalene.
- Figure 2 represents the pigmentation scores at the end of the study (D57) with (D] acetone, ( ⁇ U) hydroquinone, 13 adapalene, adapalene + hydroquinone with or without ultraviolet B irradiation.
- Depigmenting activity hydroquinone alone at 3% induces a clinically visible depigmentation from the 6th week of treatment (D43) and a statistically significant depigmentation at the end of the study.
- Adapalene alone does not modify the natural pigmentation. When adapalene is combined with Hydroquinone, it potentiates its depigmenting activity.
- hydroquinone shows an anti- pigmenting effect at the 6th and at the 7th week (D50) which becomes less marked at the end of the study.
- the adapalene + hydroquinone combination inhibits the pigmentation induced by UVB irradiation from its appearance and up to the end of the study where the difference is statistically significant ( ** ,p ⁇ 0.01).
- the hydroquinone + adapalene combination exhibits a high antipigmenting activity and significantly inhibits the pigmentation induced by UVB irradiation from its appearance and up to the end of the study.
- the hydroquinone + adapalene combination has a significant benefit as depigmenting agent in relation to hydroquinone alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003270272A AU2003270272B2 (en) | 2002-09-05 | 2003-09-01 | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
EP03750634A EP1536763B1 (en) | 2002-09-05 | 2003-09-01 | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
DK03750634T DK1536763T3 (da) | 2002-09-05 | 2003-09-01 | Depigmenterende sammensætning til huden omfattende adapalen og mindst ét depigmenterende middel |
DE60314887T DE60314887T2 (de) | 2002-09-05 | 2003-09-01 | Zusammensetzung zur depigmentierung der haut, die adapalen und mindestens ein depigmentierungsmittel enthält |
BRPI0313370-2A BR0313370B1 (pt) | 2002-09-05 | 2003-09-01 | Composição despigmentante para a pele, uso de uma composição despigmentante para a pele, uso cosmético da mesma e método para tratamento cosmético não-terapêutico |
JP2004533511A JP4662769B2 (ja) | 2002-09-05 | 2003-09-01 | アダパレンおよび少なくとも一つの色素脱失剤を含む皮膚用色素脱失組成物 |
MXPA05002064A MXPA05002064A (es) | 2002-09-05 | 2003-09-01 | Composicion despigmentante de la piel que comprende adapaleno y al menos un agente despigmentante. |
CA002495043A CA2495043A1 (en) | 2002-09-05 | 2003-09-01 | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
SI200330872T SI1536763T1 (sl) | 2002-09-05 | 2003-09-01 | Depigmentacijski sestavek za koĹľo, ki vsebuje adapalen in vsaj eno depigmentacijsko sredstvo |
US11/042,519 US20050163731A1 (en) | 2002-09-05 | 2005-01-26 | Skin depigmenting compositions comprising adapalene and at least one depigmenting active agent |
ZA2005/01753A ZA200501753B (en) | 2002-09-05 | 2005-03-01 | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0211022 | 2002-09-05 | ||
FR0211022 | 2002-09-05 | ||
US41135002P | 2002-09-18 | 2002-09-18 | |
US60/411,350 | 2002-09-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/042,519 Continuation US20050163731A1 (en) | 2002-09-05 | 2005-01-26 | Skin depigmenting compositions comprising adapalene and at least one depigmenting active agent |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004021967A2 true WO2004021967A2 (en) | 2004-03-18 |
WO2004021967A3 WO2004021967A3 (en) | 2005-02-17 |
Family
ID=31979939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/010692 WO2004021967A2 (en) | 2002-09-05 | 2003-09-01 | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
Country Status (19)
Country | Link |
---|---|
US (1) | US20050163731A1 (es) |
EP (1) | EP1536763B1 (es) |
JP (1) | JP4662769B2 (es) |
KR (1) | KR20050057238A (es) |
CN (1) | CN100391432C (es) |
AT (1) | ATE366566T1 (es) |
AU (1) | AU2003270272B2 (es) |
BR (1) | BR0313370B1 (es) |
CA (1) | CA2495043A1 (es) |
CY (1) | CY1107732T1 (es) |
DE (1) | DE60314887T2 (es) |
DK (1) | DK1536763T3 (es) |
ES (1) | ES2289315T3 (es) |
MX (1) | MXPA05002064A (es) |
PL (1) | PL377106A1 (es) |
PT (1) | PT1536763E (es) |
RU (1) | RU2317066C2 (es) |
WO (1) | WO2004021967A2 (es) |
ZA (1) | ZA200501753B (es) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052353A2 (en) * | 2002-12-12 | 2004-06-24 | Galderma Research & Development, Snc | Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid |
FR2871377A1 (fr) * | 2004-06-11 | 2005-12-16 | Galderma Res & Dev | Gel depigmentant hydroalcoolique comprenant du mequinol et de l'adapalene |
FR2890314A1 (fr) * | 2005-09-02 | 2007-03-09 | Galderma Res & Dev | Compositiondepigmentante de la peau comprenant de l'adapalene au moins un agent depigmentant et au moins un agent anti-inflammatoire |
WO2007052157A2 (en) * | 2005-09-02 | 2007-05-10 | Galderma Research & Development | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
FR2894820A1 (fr) * | 2005-12-15 | 2007-06-22 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations |
FR2915682A1 (fr) * | 2007-05-04 | 2008-11-07 | Galderma Res & Dev | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
US20110144213A1 (en) * | 2008-05-30 | 2011-06-16 | Claire Mallard | Anhydrous depigmenting compositions comprising a solubilized phenolic compound |
US20110152372A1 (en) * | 2008-05-30 | 2011-06-23 | Galderma Research & Development | Anhydrous petroleum jelly/elastomer-free depigmenting compositions comprising a solubilized phenolic compound and a retinoid |
WO2011135090A1 (en) * | 2010-04-29 | 2011-11-03 | Galderma Research & Development | Method for treating scars with adapalene 0.3% |
GB2568758A (en) * | 2017-11-28 | 2019-05-29 | Chitty Nicholas | Sun protection and acne treatment and prevention composition |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2910320B1 (fr) | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
FR2910321B1 (fr) | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | Gel creme comprenant au moins un retinoide et du peroxyde de benzole |
JP5646129B2 (ja) * | 2007-03-31 | 2014-12-24 | 大正製薬株式会社 | アダパレン含有外用剤組成物 |
US9364424B2 (en) * | 2007-11-19 | 2016-06-14 | Stiefel Laboratories, Inc. | Topical cosmetic skin lightening compositions and methods of use thereof |
FR2949065B1 (fr) | 2009-08-17 | 2011-10-21 | Natura Cosmeticos Sa | Complexe eclaircissant la peau, utilisation dudit complexe, composition cosmetique ou pharmaceutique comprenant ledit complexe et procede pour son application |
FR2969492B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene |
RU2450836C1 (ru) * | 2011-03-15 | 2012-05-20 | Закрытое акционерное общество Фармацевтическое научно-производственное предприятие "Ретиноиды" | Комбинированная мазевая композиция для уменьшения интенсивности локальной гиперпигментации кожи |
US20220211597A1 (en) * | 2021-01-07 | 2022-07-07 | Actera Ingredients, Inc. | Lipophilic third generation retinoid |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0698392A1 (fr) * | 1994-08-02 | 1996-02-28 | L'oreal | Compositions contenant et ligand spécifique de RAR alpha et au moins un acide gras |
EP0826368A1 (fr) * | 1996-09-02 | 1998-03-04 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Utilisation de rétinoides pour la préparation d'un médicament destiné à traiter les affections liées à une surexpression de VEGF |
WO1999056720A1 (en) * | 1998-05-07 | 1999-11-11 | The Procter & Gamble Company | A composition containing an ascorbic acid compound |
WO2001013882A1 (en) * | 1999-08-24 | 2001-03-01 | The Procter & Gamble Company | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
WO2001082880A2 (en) * | 2000-05-03 | 2001-11-08 | Goodman David S | Topical preparation for the treatment of hair loss |
WO2002094251A1 (en) * | 2001-05-23 | 2002-11-28 | Medicis Pharmaceutical Corp. | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
WO2002094291A1 (en) * | 2001-05-23 | 2002-11-28 | Medicis Pharmaceutical Corp. | Composition and method for the treatment of pigmentation disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856934A (en) * | 1970-06-24 | 1974-12-24 | A Kligman | Skin depigmentation |
US5194247A (en) * | 1989-08-24 | 1993-03-16 | Xina Nair | Synergistic skin depigmentation composition |
US5395611A (en) * | 1990-04-24 | 1995-03-07 | The Governors Of The University Of Alberta | Phenolic amine depigmenting and antimelanoma agents |
US6068834A (en) * | 1994-03-04 | 2000-05-30 | The Procter & Gamble Company | Skin lightening compositions |
US20030077301A1 (en) * | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
US20030147977A1 (en) * | 2000-05-03 | 2003-08-07 | Goodman David S. | Topical preparation for treating acne and hirsutism |
AU2001282399A1 (en) * | 2000-09-11 | 2002-03-22 | Pfizer Products Inc. | Resorcinol derivatives |
-
2003
- 2003-09-01 PT PT03750634T patent/PT1536763E/pt unknown
- 2003-09-01 BR BRPI0313370-2A patent/BR0313370B1/pt not_active IP Right Cessation
- 2003-09-01 RU RU2005109553/15A patent/RU2317066C2/ru not_active IP Right Cessation
- 2003-09-01 MX MXPA05002064A patent/MXPA05002064A/es active IP Right Grant
- 2003-09-01 EP EP03750634A patent/EP1536763B1/en not_active Expired - Lifetime
- 2003-09-01 WO PCT/EP2003/010692 patent/WO2004021967A2/en active IP Right Grant
- 2003-09-01 JP JP2004533511A patent/JP4662769B2/ja not_active Expired - Fee Related
- 2003-09-01 CN CNB038212447A patent/CN100391432C/zh not_active Expired - Fee Related
- 2003-09-01 AT AT03750634T patent/ATE366566T1/de active
- 2003-09-01 CA CA002495043A patent/CA2495043A1/en not_active Abandoned
- 2003-09-01 PL PL377106A patent/PL377106A1/pl not_active Application Discontinuation
- 2003-09-01 DE DE60314887T patent/DE60314887T2/de not_active Expired - Lifetime
- 2003-09-01 ES ES03750634T patent/ES2289315T3/es not_active Expired - Lifetime
- 2003-09-01 DK DK03750634T patent/DK1536763T3/da active
- 2003-09-01 AU AU2003270272A patent/AU2003270272B2/en not_active Ceased
- 2003-09-01 KR KR1020057003877A patent/KR20050057238A/ko not_active Application Discontinuation
-
2005
- 2005-01-26 US US11/042,519 patent/US20050163731A1/en not_active Abandoned
- 2005-03-01 ZA ZA2005/01753A patent/ZA200501753B/en unknown
-
2007
- 2007-09-12 CY CY20071101173T patent/CY1107732T1/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0698392A1 (fr) * | 1994-08-02 | 1996-02-28 | L'oreal | Compositions contenant et ligand spécifique de RAR alpha et au moins un acide gras |
EP0826368A1 (fr) * | 1996-09-02 | 1998-03-04 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Utilisation de rétinoides pour la préparation d'un médicament destiné à traiter les affections liées à une surexpression de VEGF |
WO1999056720A1 (en) * | 1998-05-07 | 1999-11-11 | The Procter & Gamble Company | A composition containing an ascorbic acid compound |
WO2001013882A1 (en) * | 1999-08-24 | 2001-03-01 | The Procter & Gamble Company | Methods of lightening keratinous tissue by topical application of oxime compound containing compositions |
WO2001082880A2 (en) * | 2000-05-03 | 2001-11-08 | Goodman David S | Topical preparation for the treatment of hair loss |
US20020155180A1 (en) * | 2000-05-03 | 2002-10-24 | Goodman David S. | Topical preparation for treating acne and hirsutism |
WO2002094251A1 (en) * | 2001-05-23 | 2002-11-28 | Medicis Pharmaceutical Corp. | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
WO2002094291A1 (en) * | 2001-05-23 | 2002-11-28 | Medicis Pharmaceutical Corp. | Composition and method for the treatment of pigmentation disorders |
Non-Patent Citations (2)
Title |
---|
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002241289 retrieved from STN Database accession no. 1998:730792XP000978008 * |
USATINE ET AL: "Acne vulgaris: atreatment update" HOPITAL PRACTICE, vol. 33, no. 2, 15 February 1998 (1998-02-15), pages 111-127, XP000978008 USA * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247395B2 (en) | 2002-10-25 | 2012-08-21 | Galderma S.A. | Topical skin care composition |
US8653053B2 (en) | 2002-10-25 | 2014-02-18 | Galderma S.A. | Topical skin care composition |
US7939516B2 (en) | 2002-10-25 | 2011-05-10 | Galderma S.A. | Topical skin care composition |
US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
US9333172B2 (en) | 2002-10-25 | 2016-05-10 | Galderma S.A. | Topical skin care composition |
WO2004052353A3 (en) * | 2002-12-12 | 2004-07-15 | Galderma Res & Dev | Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid |
WO2004052353A2 (en) * | 2002-12-12 | 2004-06-24 | Galderma Research & Development, Snc | Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid |
FR2871377A1 (fr) * | 2004-06-11 | 2005-12-16 | Galderma Res & Dev | Gel depigmentant hydroalcoolique comprenant du mequinol et de l'adapalene |
WO2006003299A1 (fr) * | 2004-06-11 | 2006-01-12 | Galderma Research & Development, S.N.C. | Gel dépigmentant hydroalcoolique comprenant du méquinol et de l'adapalène |
WO2007052157A3 (en) * | 2005-09-02 | 2007-10-04 | Galderma Res & Dev | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
WO2007052157A2 (en) * | 2005-09-02 | 2007-05-10 | Galderma Research & Development | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
FR2890314A1 (fr) * | 2005-09-02 | 2007-03-09 | Galderma Res & Dev | Compositiondepigmentante de la peau comprenant de l'adapalene au moins un agent depigmentant et au moins un agent anti-inflammatoire |
WO2007071861A3 (fr) * | 2005-12-15 | 2007-10-04 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations |
WO2007071861A2 (fr) * | 2005-12-15 | 2007-06-28 | Galderma Research & Development | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations |
FR2894820A1 (fr) * | 2005-12-15 | 2007-06-22 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations |
FR2915682A1 (fr) * | 2007-05-04 | 2008-11-07 | Galderma Res & Dev | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
WO2008148968A1 (fr) * | 2007-05-04 | 2008-12-11 | Galderma Research & Development | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
US20110152372A1 (en) * | 2008-05-30 | 2011-06-23 | Galderma Research & Development | Anhydrous petroleum jelly/elastomer-free depigmenting compositions comprising a solubilized phenolic compound and a retinoid |
US20110144213A1 (en) * | 2008-05-30 | 2011-06-16 | Claire Mallard | Anhydrous depigmenting compositions comprising a solubilized phenolic compound |
WO2011135090A1 (en) * | 2010-04-29 | 2011-11-03 | Galderma Research & Development | Method for treating scars with adapalene 0.3% |
US20130203850A1 (en) * | 2010-04-29 | 2013-08-08 | Galderma Research & Development | Method for treating scars with adapalene 0.3% |
GB2568758A (en) * | 2017-11-28 | 2019-05-29 | Chitty Nicholas | Sun protection and acne treatment and prevention composition |
Also Published As
Publication number | Publication date |
---|---|
DK1536763T3 (da) | 2007-11-05 |
DE60314887D1 (de) | 2007-08-23 |
EP1536763B1 (en) | 2007-07-11 |
CY1107732T1 (el) | 2013-04-18 |
RU2005109553A (ru) | 2005-08-20 |
RU2317066C2 (ru) | 2008-02-20 |
JP2006511466A (ja) | 2006-04-06 |
EP1536763A2 (en) | 2005-06-08 |
AU2003270272B2 (en) | 2008-06-19 |
PL377106A1 (pl) | 2006-01-23 |
AU2003270272A1 (en) | 2004-03-29 |
ATE366566T1 (de) | 2007-08-15 |
CN100391432C (zh) | 2008-06-04 |
KR20050057238A (ko) | 2005-06-16 |
US20050163731A1 (en) | 2005-07-28 |
ES2289315T3 (es) | 2008-02-01 |
BR0313370B1 (pt) | 2015-02-24 |
WO2004021967A3 (en) | 2005-02-17 |
CN1681473A (zh) | 2005-10-12 |
CA2495043A1 (en) | 2004-03-18 |
JP4662769B2 (ja) | 2011-03-30 |
ZA200501753B (en) | 2007-01-31 |
DE60314887T2 (de) | 2008-03-13 |
BR0313370A (pt) | 2006-04-18 |
MXPA05002064A (es) | 2005-06-08 |
PT1536763E (pt) | 2007-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050163731A1 (en) | Skin depigmenting compositions comprising adapalene and at least one depigmenting active agent | |
US11896696B2 (en) | Methods of skin whitening by use of canola extracts | |
EP2144590B1 (en) | Skin treatment compositions and methods | |
US20100189795A1 (en) | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions | |
US20090137534A1 (en) | Skin treatment compositions and methods | |
WO2008045272A2 (en) | Compositions and methods for skin lightening | |
CA2429935C (en) | Compositions and methods for treating hyperpigmentation | |
US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
JP2003137714A (ja) | 化粧用組成物又は医薬用組成物 | |
CN109195578B (zh) | 硫代磷酸酯衍生物作为皮肤脱色剂的用途 | |
JP2011513192A (ja) | 皮膚の脱色における使用のためのフルオシノロンアセトニドを含む局所用組成物 | |
EP1813312A2 (en) | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent | |
Mashhood | Treatment of hyperpigmentation disorders | |
WO2024056568A1 (en) | Skin depigmentation composition and use thereof | |
Zhai et al. | Skin-whitening products | |
CA2616915A1 (en) | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent | |
Rendon et al. | 15 Skin Lightening Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003750634 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003270272 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11042519 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2495043 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/002064 Country of ref document: MX Ref document number: 377106 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01753 Country of ref document: ZA Ref document number: 200501753 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004533511 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057003877 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038212447 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005109553 Country of ref document: RU Kind code of ref document: A |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003750634 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057003877 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0313370 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003750634 Country of ref document: EP |